ClinicalTrials.gg
CompletedNCT05564052VEGAUpdated Oct 7, 2025Results posted

A Study of Ibrutinib With Rituximab in Relapsed or Refractory Mantle Cell Lymphoma

A Phase 2 interventional study of Ibrutinib and Lenalidomide in Lymphoma, Mantle-Cell, sponsored by Janssen Research & Development, LLC. Completed at 66 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-10-07.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 45 studies testing ibrutinib in Lymphoma, Mantle-Cell — 2 open to participants now, 16 under way, 2 of them phase 3. ibrutinib · Lymphoma, Mantle-Cell.

Enrollment
25th of 45
36 · median 39
Started
2022
with 1 other
Phase 2
21 of 45
none open now
Registered
43rd of 45
by date
Lead sponsor
6 of 45
Janssen Research & Development, LLC

Among the 45 studies testing ibrutinib in Lymphoma, Mantle-Cell, this one is the 25th largest by enrollment, is one of 2 that started in 2022, is one of 21 in phase 2, and was the 43rd registered.

Lymphoma, Mantle-Cell

1,221 studies on the registry are indexed under Lymphoma, Mantle-Cell; 154 are open to participants now.

Browse Lymphoma, Mantle-Cell studies →

Open to participants now

2 of the 45 studies testing ibrutinib in Lymphoma, Mantle-Cell are open now, in 6 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About ibrutinib

ibrutinib: first FDA approval 2013 (IMBRUVICA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 124 Lymphoma, Mantle-Cell studies recruiting now, 92 (74%) set no upper age limit and 12 (10%) stop at 75 or younger; 14 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 45 studies testing ibrutinib in Lymphoma, Mantle-Cell, or all of them as a file.
02

Study summary

The purpose of this study is to provide continued access to treatment for participants who continue to benefit from treatment.

Read the detailed description

Mantle cell lymphoma (MCL) is an uncommon and incurable clinicopathologic subtype of B-cell non-Hodgkin Lymphoma (NHL). Ibrutinib is a first-in-class potent, orally administered, covalently-binding small molecule inhibitor of Bruton's tyrosine kinase (BTKi) for the treatment of B-cell malignancies and chronic graft-versus-host disease. The primary hypothesis of the study is to provide continued access to treatment for participants who continue to benefit from treatment. The study will include a screening phase (up to 30 days prior to randomization), a treatment phase (from randomization until study treatment discontinuation). safety assessments include adverse events (AEs), serious adverse events (SAEs), clinical laboratory tests, vital signs, electrocardiogram (ECG), physical examination. The Phase 2 exploratory objectives and endpoints of characterization of pharmacokinetic and pharmacodynamic of ibrutinib may continue to be evaluated using blood samples already collected. The total duration of the study will be up to 2 years 1 month.

03

Conditions studied

  • Lymphoma, Mantle-Cell
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • At least 1 prior treatment regimen for mantle cell lymphoma (MCL) excluding inhibitor of Bruton's tyrosine kinase (BTKi)
  • Documented disease progression or relapse following the last anti-MCL treatment
  • At least 1 measurable site of disease on cross-sectional imaging that is greater than or equal to (>=) 2.0 centimeters (cm) in the longest diameter and measurable in 2 perpendicular dimensions per computed tomography (CT)
  • (ECOG) performance status score 0 or 1

Exclusion criteria

Exclusion Criteria:

  • Prior therapy with ibrutinib or other BTK inhibitor
  • Prior treatment with both lenalidomide and bortezomib. Prior treatment with only 1 of these therapies is allowed
  • Major surgery within 4 weeks of randomization
  • Concurrent enrollment in another therapeutic study
  • Known central nervous system lymphoma
  • History of stroke or intracranial hemorrhage within 6 months prior to randomization
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    Phase 2: Treatment Arm A1 (Rituximab plus Ibrutinib)

    Participants will receive rituximab 375 milligrams per meter square (mg/m\^2) intravenously (IV) on Day 1 of Cycles 1 to 6 with ibrutinib 560 milligrams (mg) orally, once daily starting on Day 1 of Cycle 1 until disease progression or unacceptable toxicity (each cycle length is 28 days).

    Drug: Ibrutinib · Drug: Rituximab

  • Experimental
    Phase 2: Treatment Arm A2 (Rituximab plus Ibrutinib)

    Participants will receive rituximab 375 mg/m\^2 IV on Day 1 of Cycles 1 to 6 with ibrutinib 420 mg orally, once daily starting on Day 1 of Cycle 1 until disease progression or unacceptable toxicity (each cycle length is 28 days).

    Drug: Ibrutinib · Drug: Rituximab

  • Experimental
    Phase 2: Treatment Arm A3 (Rituximab plus Ibrutinib)

    Participants will receive rituximab 375 mg/m\^2 IV on Day 1 of Cycles 1 to 6 with ibrutinib 140 mg orally, twice daily starting on Day 1 of Cycle 1 until disease progression or unacceptable toxicity (each cycle length is 28 days).

    Drug: Ibrutinib · Drug: Rituximab

  • Experimental
    Phase 2: Treatment Arm B (Rituximab plus Lenalidomide or Bortezomib)

    Participants will receive rituximab 375 mg/m\^2 IV on Day 1 of Cycles 1 to 6 (each cycle length is 21 or 28 days) with physician's choice of either lenalidomide 20 mg orally, once daily from Day 1 through Day 21 of 28-day cycle or bortezomib 1.3 mg/m\^2 IV or subcutaneously (SC) on Days 1, 4, 8 and 11 of a 21-day cycle until disease progression or unacceptable toxicity.

    Drug: Lenalidomide · Drug: Rituximab · Drug: Bortezomib

Interventions

  • Ibrutinib capsules will be administered orally.

    Also known as: JNJ-54179060, IMBRUVICA, PCI-32765

  • Lenalidomide capsules will be administered orally.

  • Rituximab will be administered IV.

  • Bortezomib will be administered either intravenously or subcutaneously.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment Emergent Adverse Events (TEAEs) Leading to Discontinuation of Treatment: Arms A1, A2, A3 and B

    An adverse event (AE) was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. TEAEs was defined as any new or worsening AE occurring at or after first dose of study treatment up to 30 days after last dose or prior to start of subsequent anticancer therapy, whichever occurred first. All TEAEs including serious and non-serious events were reported in this outcome measure.

    Time frame: From start of treatment (Day 1) up to 30 days after last dose of study drug or start of subsequent anticancer therapy, whichever occurred first (up to 12 months)

  2. Number of Participants With Treatment Emergent Adverse Events (TEAEs) Leading to Discontinuation of Treatment: Monotherapy Arm

    An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. TEAEs was defined as any new or worsening AE occurring at or after first dose of study treatment up to 30 days after last dose or prior to start of subsequent anticancer therapy, whichever occurred first. All TEAEs included serious and non-serious events were reported in this outcome measure.

    Time frame: From start of monotherapy (post protocol amendment 1, dated 08 June 2023) up to 30 days after last dose of study drug or start of subsequent anticancer therapy, whichever occurred first (up to 6 months)

  3. Number of Participants With Grade 3 or Higher TEAEs Based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version (v) 5.0: Arms A1, A2, A3 and B

    An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. TEAEs was defined as any new or worsening AE occurring at or after first dose of study treatment up to 30 days after last dose or prior to start of subsequent anticancer therapy, whichever occurred first. TEAEs were graded according to NCI-CTCAE v5.0 as Grade 1- Mild; Grade 2- Moderate; Grade 3- Severe or medically significant but not immediately life-threatening; Grade 4- Life-threatening consequences and Grade 5- Death related to AE. Number of participants with grade 3 or higher TEAEs (including serious and non-serious events) were reported in this outcome measure.

    Time frame: From start of treatment (Day 1) up to 30 days after last dose of study drug or start of subsequent anticancer therapy, whichever occurred first (up to 12 months)

  4. Number of Participants With Grade 3 or Higher TEAEs Based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version (v) 5.0: Monotherapy Arm

    An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. TEAEs was defined as any new or worsening AE occurring at or after first dose of study treatment up to 30 days after last dose or prior to start of subsequent anticancer therapy, whichever occurred first. TEAEs were graded according to NCI-CTCAE v5.0 as Grade 1- Mild; Grade 2- Moderate; Grade 3- Severe or medically significant but not immediately life-threatening; Grade 4- Life-threatening consequences and Grade 5- Death related to AE. Number of participants with grade 3 or higher TEAEs (including serious and non-serious events) were reported in this outcome measure.

    Time frame: From start of monotherapy (post protocol amendment 1, dated 08 June 2023) up to 30 days after last dose of study drug or start of subsequent anticancer therapy, whichever occurred first (up to 6 months)

  5. Number of Participants With Treatment Emergent Serious Adverse Events (TESAEs): Arms A1, A2, A3 and B

    An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. A serious AE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was a suspected transmission of any infectious agent via a medicinal product, or was medically important. TESAEs was defined as SAEs occurring at or after first dose of study treatment up to 30 days after last dose or prior to start of subsequent anticancer therapy, whichever occurred first.

    Time frame: From start of treatment (Day 1) up to 30 days after last dose of study drug or start of subsequent anticancer therapy, whichever occurred first (up to 12 months)

  6. Number of Participants With Treatment Emergent Serious Adverse Events (TESAEs): Monotherapy Arm

    An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. A serious AE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was a suspected transmission of any infectious agent via a medicinal product, or was medically important. TESAEs was defined as SAEs occurring at or after first dose of study treatment up to 30 days after last dose or prior to start of subsequent anticancer therapy, whichever occurred first.

    Time frame: From start of monotherapy (post protocol amendment 1, dated 08 June 2023) up to 30 days after last dose of study drug or start of subsequent anticancer therapy, whichever occurred first (up to 6 months)

  7. Number of Participants With Clinical Laboratory Abnormalities: Hematology Parameters: Arms A1, A2, A3 and B

    Number of participants with clinical abnormalities in hematology laboratory parameters were reported. Hematology parameters included: Activated partial thromboplastin time (aPTT), hemoglobin, neutrophil count, white blood cell (WBC) count, lymphocyte count, platelet count and prothrombin international normalized ratio (INR). Abnormality criteria was assessed as per NCI CTCAE v5.0 grading, where Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life-threatening. Grade 0 was assigned when the laboratory value was not assigned a Grade 1 or higher. Only those categories in which at least 1 participant had data were reported.

    Time frame: From start of treatment (Day 1) up to 30 days after last dose of study drug (up to 12 months)

  8. Number of Participants With Clinical Laboratory Abnormalities: Hematology Parameters: Monotherapy Arm

    Number of participants with clinical abnormalities in hematology laboratory parameters were reported. Hematology parameters included: Activated partial thromboplastin time (aPTT), hemoglobin, neutrophil count, white blood cell (WBC) count, lymphocyte count, platelet count and prothrombin international normalized ratio (INR). Abnormality criteria was assessed as per NCI CTCAE v5.0 grading, where Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life-threatening. Grade 0 was assigned when the laboratory value was not assigned a Grade 1 or higher. Only those categories in which at least 1 participant had data were reported.

    Time frame: From start of monotherapy (post protocol amendment 1, dated 08 June 2023) up to 30 days after last dose of study drug (up to 6 months)

  9. Number of Participants With Clinical Laboratory Abnormalities: Chemistry Parameters: Arms A1, A2, A3 and B

    Number of participants with clinical abnormalities in chemistry laboratory parameters were reported. Chemistry parameters included: sodium, aspartate aminotransferase (AST), potassium, alanine aminotransferase (ALT), creatinine, total bilirubin (BL), alkaline phosphatase, albumin, and calcium. Abnormality criteria was assessed as per NCI CTCAE v5.0 grading, where Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life-threatening. Grade 0 was assigned when the laboratory value was not assigned a Grade 1 or higher. Only those categories in which at least 1 participant had data were reported.

    Time frame: From start of treatment (Day 1) up to 30 days after last dose of study drug (up to 12 months)

  10. Number of Participants With Clinical Laboratory Abnormalities: Chemistry Parameters: Monotherapy Arm

    Number of participants with clinical abnormalities in chemistry laboratory parameters were reported. Chemistry parameters included: sodium, aspartate aminotransferase (AST), potassium, alanine aminotransferase (ALT), creatinine, total bilirubin, alkaline phosphatase, albumin, and calcium. Abnormality criteria was assessed as per NCI CTCAE v5.0 grading, where Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life-threatening. Grade 0 was assigned when the laboratory value was not assigned a Grade 1 or higher. Only those categories in which at least 1 participant had data were reported.

    Time frame: From start of monotherapy (post protocol amendment 1, dated 08 June 2023) up to 30 days after last dose of study drug (up to 6 months)

07

Results

Posted Jan 13, 2025

Participant flow

Participant flow — Overall Study
MilestoneArm A1: Ibrutinib 560 mg + Rituximab 375 mg/m^2Arm A2: Ibrutinib 420 mg + Rituximab 375 mg/m^2Arm A3: Ibrutinib 140 mg + Rituximab 375 mg/m^2Arm B: Lenalidomide 20 mg (or 10 mg if CrCl Was 30 to <60 mL/Min) + Rituximab 375 mg/m^2
Started10989
Participants who switched to ibrutinib monotherapy0432
Completed10988
Not completed0001
Withdrew: Withdrawal by subject0001

Outcome measures

PrimaryNumber of Participants With Treatment Emergent Adverse Events (TEAEs) Leading to Discontinuation of Treatment: Arms A1, A2, A3 and B

An adverse event (AE) was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. TEAEs was defined as any new or worsening AE occurring at or after first dose of study treatment up to 30 days after last dose or prior to start of subsequent anticancer therapy, whichever occurred first. All TEAEs including serious and non-serious events were reported in this outcome measure.

Time frame:
From start of treatment (Day 1) up to 30 days after last dose of study drug or start of subsequent anticancer therapy, whichever occurred first (up to 12 months)
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs) Leading to Discontinuation of Treatment: Arms A1, A2, A3 and B
ParticipantsArm A1: Ibrutinib 560 mg + Rituximab 375 mg/m^2Arm A2: Ibrutinib 420 mg + Rituximab 375 mg/m^2Arm A3: Ibrutinib 140 mg + Rituximab 375 mg/m^2Arm B: Lenalidomide 20 mg (or 10 mg if CrCl Was 30 to <60 mL/Min) + Rituximab 375 mg/m^2
Discontinuation of Treatment Ibrutinib/Lenalidomide1002
Discontinuation of Treatment Rituximab0101
PrimaryNumber of Participants With Treatment Emergent Adverse Events (TEAEs) Leading to Discontinuation of Treatment: Monotherapy Arm

An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. TEAEs was defined as any new or worsening AE occurring at or after first dose of study treatment up to 30 days after last dose or prior to start of subsequent anticancer therapy, whichever occurred first. All TEAEs included serious and non-serious events were reported in this outcome measure.

Time frame:
From start of monotherapy (post protocol amendment 1, dated 08 June 2023) up to 30 days after last dose of study drug or start of subsequent anticancer therapy, whichever occurred first (up to 6 months)
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs) Leading to Discontinuation of Treatment: Monotherapy Arm
ParticipantsMonotherapy Arm: Ibrutinib 560 mg
Number of Participants With Treatment Emergent Adverse Events (TEAEs) Leading to Discontinuation of Treatment: Monotherapy Arm1
PrimaryNumber of Participants With Grade 3 or Higher TEAEs Based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version (v) 5.0: Arms A1, A2, A3 and B

An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. TEAEs was defined as any new or worsening AE occurring at or after first dose of study treatment up to 30 days after last dose or prior to start of subsequent anticancer therapy, whichever occurred first. TEAEs were graded according to NCI-CTCAE v5.0 as Grade 1- Mild; Grade 2- Moderate; Grade 3- Severe or medically significant but not immediately life-threatening; Grade 4- Life-threatening consequences and Grade 5- Death related to AE. Number of participants with grade 3 or higher TEAEs (including serious and non-serious events) were reported in this outcome measure.

Time frame:
From start of treatment (Day 1) up to 30 days after last dose of study drug or start of subsequent anticancer therapy, whichever occurred first (up to 12 months)
Reported as:
Count of participants · Participants
Number of Participants With Grade 3 or Higher TEAEs Based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version (v) 5.0: Arms A1, A2, A3 and B
ParticipantsArm A1: Ibrutinib 560 mg + Rituximab 375 mg/m^2Arm A2: Ibrutinib 420 mg + Rituximab 375 mg/m^2Arm A3: Ibrutinib 140 mg + Rituximab 375 mg/m^2Arm B: Lenalidomide 20 mg (or 10 mg if CrCl Was 30 to <60 mL/Min) + Rituximab 375 mg/m^2
Number of Participants With Grade 3 or Higher TEAEs Based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version (v) 5.0: Arms A1, A2, A3 and B7358
PrimaryNumber of Participants With Grade 3 or Higher TEAEs Based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version (v) 5.0: Monotherapy Arm

An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. TEAEs was defined as any new or worsening AE occurring at or after first dose of study treatment up to 30 days after last dose or prior to start of subsequent anticancer therapy, whichever occurred first. TEAEs were graded according to NCI-CTCAE v5.0 as Grade 1- Mild; Grade 2- Moderate; Grade 3- Severe or medically significant but not immediately life-threatening; Grade 4- Life-threatening consequences and Grade 5- Death related to AE. Number of participants with grade 3 or higher TEAEs (including serious and non-serious events) were reported in this outcome measure.

Time frame:
From start of monotherapy (post protocol amendment 1, dated 08 June 2023) up to 30 days after last dose of study drug or start of subsequent anticancer therapy, whichever occurred first (up to 6 months)
Reported as:
Count of participants · Participants
Number of Participants With Grade 3 or Higher TEAEs Based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version (v) 5.0: Monotherapy Arm
ParticipantsMonotherapy Arm: Ibrutinib 560 mg
Number of Participants With Grade 3 or Higher TEAEs Based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version (v) 5.0: Monotherapy Arm1
PrimaryNumber of Participants With Treatment Emergent Serious Adverse Events (TESAEs): Arms A1, A2, A3 and B

An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. A serious AE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was a suspected transmission of any infectious agent via a medicinal product, or was medically important. TESAEs was defined as SAEs occurring at or after first dose of study treatment up to 30 days after last dose or prior to start of subsequent anticancer therapy, whichever occurred first.

Time frame:
From start of treatment (Day 1) up to 30 days after last dose of study drug or start of subsequent anticancer therapy, whichever occurred first (up to 12 months)
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Serious Adverse Events (TESAEs): Arms A1, A2, A3 and B
ParticipantsArm A1: Ibrutinib 560 mg + Rituximab 375 mg/m^2Arm A2: Ibrutinib 420 mg + Rituximab 375 mg/m^2Arm A3: Ibrutinib 140 mg + Rituximab 375 mg/m^2Arm B: Lenalidomide 20 mg (or 10 mg if CrCl Was 30 to <60 mL/Min) + Rituximab 375 mg/m^2
Number of Participants With Treatment Emergent Serious Adverse Events (TESAEs): Arms A1, A2, A3 and B4325
PrimaryNumber of Participants With Treatment Emergent Serious Adverse Events (TESAEs): Monotherapy Arm

An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. A serious AE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was a suspected transmission of any infectious agent via a medicinal product, or was medically important. TESAEs was defined as SAEs occurring at or after first dose of study treatment up to 30 days after last dose or prior to start of subsequent anticancer therapy, whichever occurred first.

Time frame:
From start of monotherapy (post protocol amendment 1, dated 08 June 2023) up to 30 days after last dose of study drug or start of subsequent anticancer therapy, whichever occurred first (up to 6 months)
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Serious Adverse Events (TESAEs): Monotherapy Arm
ParticipantsMonotherapy Arm: Ibrutinib 560 mg
Number of Participants With Treatment Emergent Serious Adverse Events (TESAEs): Monotherapy Arm1
PrimaryNumber of Participants With Clinical Laboratory Abnormalities: Hematology Parameters: Arms A1, A2, A3 and B

Number of participants with clinical abnormalities in hematology laboratory parameters were reported. Hematology parameters included: Activated partial thromboplastin time (aPTT), hemoglobin, neutrophil count, white blood cell (WBC) count, lymphocyte count, platelet count and prothrombin international normalized ratio (INR). Abnormality criteria was assessed as per NCI CTCAE v5.0 grading, where Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life-threatening. Grade 0 was assigned when the laboratory value was not assigned a Grade 1 or higher. Only those categories in which at least 1 participant had data were reported.

Time frame:
From start of treatment (Day 1) up to 30 days after last dose of study drug (up to 12 months)
Reported as:
Count of participants · Participants
Number of Participants With Clinical Laboratory Abnormalities: Hematology Parameters: Arms A1, A2, A3 and B
ParticipantsArm A1: Ibrutinib 560 mg + Rituximab 375 mg/m^2Arm A2: Ibrutinib 420 mg + Rituximab 375 mg/m^2Arm A3: Ibrutinib 140 mg + Rituximab 375 mg/m^2Arm B: Lenalidomide 20 mg (or 10 mg if CrCl Was 30 to <60 mL/Min) + Rituximab 375 mg/m^2
aPTT Prolonged Grade 11———
Hemoglobin Decreased Grade 03220
Hemoglobin Decreased Grade 13645
Hemoglobin Decreased Grade 23111
Hemoglobin Decreased Grade 31013
Hemoglobin Increased Grade 010989
Lymphocyte Count Decreased Grade 04573
Lymphocyte Count Decreased Grade 13012
Lymphocyte Count Decreased Grade 22402
Lymphocyte Count Decreased Grade 31001
Lymphocyte Count Decreased Grade 40001
Lymphocyte Count Increased Grade 08876
Lymphocyte Count Increased Grade 22112
Lymphocyte Count Increased Grade 30001
Neutrophil Count Decreased Grade 04741
Neutrophil Count Decreased Grade 11101
Neutrophil Count Decreased Grade 21001
Neutrophil Count Decreased Grade 32142
Neutrophil Count Decreased Grade 42004
Platelet Count Decreased Grade 02251
Platelet Count Decreased Grade 14523
Platelet Count Decreased Grade 22103
Platelet Count Decreased Grade 32000
Platelet Count Decreased Grade 40112
Prothrombin INR Increased Grade 01———
WBC Decreased Grade 03453
WBC Decreased Grade 15532
WBC Decreased Grade 21003
WBC Decreased Grade 31000
WBC Decreased Grade 40001
WBC Increased Grade 010988
WBC Increased Grade 30001
PrimaryNumber of Participants With Clinical Laboratory Abnormalities: Hematology Parameters: Monotherapy Arm

Number of participants with clinical abnormalities in hematology laboratory parameters were reported. Hematology parameters included: Activated partial thromboplastin time (aPTT), hemoglobin, neutrophil count, white blood cell (WBC) count, lymphocyte count, platelet count and prothrombin international normalized ratio (INR). Abnormality criteria was assessed as per NCI CTCAE v5.0 grading, where Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life-threatening. Grade 0 was assigned when the laboratory value was not assigned a Grade 1 or higher. Only those categories in which at least 1 participant had data were reported.

Time frame:
From start of monotherapy (post protocol amendment 1, dated 08 June 2023) up to 30 days after last dose of study drug (up to 6 months)
Reported as:
Count of participants · Participants
Number of Participants With Clinical Laboratory Abnormalities: Hematology Parameters: Monotherapy Arm
ParticipantsMonotherapy Arm: Ibrutinib 560 mg
aPTT Prolonged Grade 01
Hemoglobin Increased Grade 08
Hemoglobin Decreased Grade 02
Hemoglobin Decreased Grade 15
Hemoglobin Decreased Grade 21
Lymphocyte Count Decreased Grade 05
Lymphocyte Count Decreased Grade 11
Lymphocyte Count Decreased Grade 21
Lymphocyte Count Decreased Grade 41
Lymphocyte Count Increased Grade 08
Neutrophil Count Decreased Grade 06
Neutrophil Count Decreased Grade 11
Neutrophil Count Decreased Grade 21
Platelet Count Decreased Grade 02
Platelet Count Decreased Grade 16
Prothrombin INR Increased Grade 01
WBC Decreased Grade 05
WBC Decreased Grade 13
WBC Increased Grade 08
PrimaryNumber of Participants With Clinical Laboratory Abnormalities: Chemistry Parameters: Arms A1, A2, A3 and B

Number of participants with clinical abnormalities in chemistry laboratory parameters were reported. Chemistry parameters included: sodium, aspartate aminotransferase (AST), potassium, alanine aminotransferase (ALT), creatinine, total bilirubin (BL), alkaline phosphatase, albumin, and calcium. Abnormality criteria was assessed as per NCI CTCAE v5.0 grading, where Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life-threatening. Grade 0 was assigned when the laboratory value was not assigned a Grade 1 or higher. Only those categories in which at least 1 participant had data were reported.

Time frame:
From start of treatment (Day 1) up to 30 days after last dose of study drug (up to 12 months)
Reported as:
Count of participants · Participants
Number of Participants With Clinical Laboratory Abnormalities: Chemistry Parameters: Arms A1, A2, A3 and B
ParticipantsArm A1: Ibrutinib 560 mg + Rituximab 375 mg/m^2Arm A2: Ibrutinib 420 mg + Rituximab 375 mg/m^2Arm A3: Ibrutinib 140 mg + Rituximab 375 mg/m^2Arm B: Lenalidomide 20 mg (or 10 mg if CrCl Was 30 to <60 mL/Min) + Rituximab 375 mg/m^2
ALT Increased Grade 05986
ALT Increased Grade 14003
ALT Increased Grade 31000
Albumin Decreased Grade 06947
Albumin Decreased Grade 12041
Albumin Decreased Grade 22001
Alkaline Phosphatase (AP) Increased Grade 08857
AP Increased Grade 12132
AST Increased Grade 05886
AST Increased Grade 14103
AST Increased Grade 31000
Bilirubin (BL) Increased Grade 07778
BL Increased Grade 12201
BL Increased Grade 20010
BL Increased Grade 31000
Calcium Corrected Decreased Grade 07766
Calcium Corrected Decreased Grade 13222
Calcium Corrected Decreased Grade 20001
Calcium Corrected Increased Grade 010988
Calcium Corrected Increased Grade 10001
Creatinine Increased Grade 09746
Creatinine Increased Grade 11223
Creatinine Increased Grade 20020
Potassium Decreased Grade 07769
Potassium Decreased Grade 22120
Potassium Decreased Grade 41100
Potassium Increased Grade 010879
Potassium Increased Grade 20110
Sodium Decreased Grade 07658
Sodium Decreased Grade 13331
Sodium Increased Grade 08988
Sodium Increased Grade 12001
PrimaryNumber of Participants With Clinical Laboratory Abnormalities: Chemistry Parameters: Monotherapy Arm

Number of participants with clinical abnormalities in chemistry laboratory parameters were reported. Chemistry parameters included: sodium, aspartate aminotransferase (AST), potassium, alanine aminotransferase (ALT), creatinine, total bilirubin, alkaline phosphatase, albumin, and calcium. Abnormality criteria was assessed as per NCI CTCAE v5.0 grading, where Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life-threatening. Grade 0 was assigned when the laboratory value was not assigned a Grade 1 or higher. Only those categories in which at least 1 participant had data were reported.

Time frame:
From start of monotherapy (post protocol amendment 1, dated 08 June 2023) up to 30 days after last dose of study drug (up to 6 months)
Reported as:
Count of participants · Participants
Number of Participants With Clinical Laboratory Abnormalities: Chemistry Parameters: Monotherapy Arm
ParticipantsMonotherapy Arm: Ibrutinib 560 mg
ALT Increased Grade 08
Albumin Decreased Grade 06
Albumin Decreased Grade 12
Alkaline Phosphatase Increased Grade 08
AST Increased Grade 08
Bilirubin Increased Grade 08
Calcium Corrected Decreased Grade 07
Calcium Corrected Decreased Grade 11
Calcium Corrected Increased Grade 08
Creatinine Increased Grade 07
Creatinine Increased Grade 11
Potassium Decreased Grade 07
Potassium Decreased Grade 21
Potassium Increased Grade 08
Sodium Decreased Grade 05
Sodium Decreased Grade 13
Sodium Increased Grade 08

Adverse events

Collected over Arm A1, A2, A3 and B: From start of treatment (Day 1) up to 30 days after last dose of study drug or start of subsequent anticancer therapy, whichever occurred first (up to 12 months); Monotherapy arm: From start of monotherapy (post protocol amendment 1, dated 08 June 2023) up to 30 days after last dose of study drug or start of subsequent anticancer therapy, whichever occurred first (up to 6 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm A1: Ibrutinib 560 mg + Rituximab 375 mg/m^21/10 (10%)4/10 (40%)10/10 (100%)
Arm A2: Ibrutinib 420 mg + Rituximab 375 mg/m^20/9 (0%)3/9 (33.3%)7/9 (77.8%)
Arm A3: Ibrutinib 140 mg + Rituximab 375 mg/m^21/8 (12.5%)2/8 (25%)8/8 (100%)
Arm B: Lenalidomide 20 mg (or 10 mg if CrCl Was 30 to <60 mL/Min) + Rituximab 375 mg/m^22/9 (22.2%)5/9 (55.6%)8/9 (88.9%)
Monotherapy Arm: Ibrutinib 560 mg0/9 (0%)1/9 (11.1%)4/9 (44.4%)
Most frequent serious events
Showing 10 of 14
Most frequent serious events
EventArm A1: Ibrutinib 560 mg + Rituximab 375 mg/m^2Arm A2: Ibrutinib 420 mg + Rituximab 375 mg/m^2Arm A3: Ibrutinib 140 mg + Rituximab 375 mg/m^2Arm B: Lenalidomide 20 mg (or 10 mg if CrCl Was 30 to <60 mL/Min) + Rituximab 375 mg/m^2Monotherapy Arm: Ibrutinib 560 mg
Febrile NeutropeniaBlood and lymphatic system disorders0/100/90/82/90/9
PneumoniaInfections and infestations0/101/91/80/91/9
Papillary Thyroid CancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/100/91/80/90/9
ThrombocytopeniaBlood and lymphatic system disorders0/101/90/81/90/9
Supraventricular TachycardiaCardiac disorders0/101/90/80/90/9
SepsisInfections and infestations0/100/90/81/90/9
Septic ShockInfections and infestations0/100/90/81/90/9
Skin InfectionInfections and infestations0/100/90/81/90/9
Adenocarcinoma MetastaticNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/101/90/80/90/9
NeutropeniaBlood and lymphatic system disorders1/100/90/80/90/9
Most frequent other events
Showing 10 of 101
Most frequent other events
EventArm A1: Ibrutinib 560 mg + Rituximab 375 mg/m^2Arm A2: Ibrutinib 420 mg + Rituximab 375 mg/m^2Arm A3: Ibrutinib 140 mg + Rituximab 375 mg/m^2Arm B: Lenalidomide 20 mg (or 10 mg if CrCl Was 30 to <60 mL/Min) + Rituximab 375 mg/m^2Monotherapy Arm: Ibrutinib 560 mg
NeutropeniaBlood and lymphatic system disorders4/101/94/84/90/9
HypertensionVascular disorders5/101/90/80/90/9
DiarrhoeaGastrointestinal disorders1/100/93/80/90/9
AnaemiaBlood and lymphatic system disorders1/100/91/83/90/9
ThrombocytopeniaBlood and lymphatic system disorders1/100/90/83/90/9
Periorbital OedemaEye disorders0/100/92/80/90/9
Blood Creatinine IncreasedInvestigations0/100/92/80/90/9
Platelet Count DecreasedInvestigations0/100/92/82/90/9
PneumoniaInfections and infestations0/102/91/80/90/9
Upper Respiratory Tract InfectionInfections and infestations2/101/90/81/91/9

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Arm A1: Ibrutinib 560 mg + Rituximab 375 mg/m^2Arm A2: Ibrutinib 420 mg + Rituximab 375 mg/m^2Arm A3: Ibrutinib 140 mg + Rituximab 375 mg/m^2Arm B: Lenalidomide 20 mg (or 10 mg if CrCl Was 30 to <60 mL/Min) + Rituximab 375 mg/m^2Total
Mean66.5 ± 7.2368.9 ± 8.0864.6 ± 10.3564.6 ± 7.6066.2 ± 8.13
Sex: Female, Male
Sex: Female, Male(Participants)Arm A1: Ibrutinib 560 mg + Rituximab 375 mg/m^2Arm A2: Ibrutinib 420 mg + Rituximab 375 mg/m^2Arm A3: Ibrutinib 140 mg + Rituximab 375 mg/m^2Arm B: Lenalidomide 20 mg (or 10 mg if CrCl Was 30 to <60 mL/Min) + Rituximab 375 mg/m^2Total
Female43119
Male667827
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Arm A1: Ibrutinib 560 mg + Rituximab 375 mg/m^2Arm A2: Ibrutinib 420 mg + Rituximab 375 mg/m^2Arm A3: Ibrutinib 140 mg + Rituximab 375 mg/m^2Arm B: Lenalidomide 20 mg (or 10 mg if CrCl Was 30 to <60 mL/Min) + Rituximab 375 mg/m^2Total
Hispanic or Latino322310
Not Hispanic or Latino776626
Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Arm A1: Ibrutinib 560 mg + Rituximab 375 mg/m^2Arm A2: Ibrutinib 420 mg + Rituximab 375 mg/m^2Arm A3: Ibrutinib 140 mg + Rituximab 375 mg/m^2Arm B: Lenalidomide 20 mg (or 10 mg if CrCl Was 30 to <60 mL/Min) + Rituximab 375 mg/m^2Total
American Indian or Alaska Native00000
Asian22228
Native Hawaiian or Other Pacific Islander00000
Black or African American10124
White674522
More than one race00000
Unknown or Not Reported10102
Region of Enrollment
Region of Enrollment(Participants)Arm A1: Ibrutinib 560 mg + Rituximab 375 mg/m^2Arm A2: Ibrutinib 420 mg + Rituximab 375 mg/m^2Arm A3: Ibrutinib 140 mg + Rituximab 375 mg/m^2Arm B: Lenalidomide 20 mg (or 10 mg if CrCl Was 30 to <60 mL/Min) + Rituximab 375 mg/m^2Total
BRAZIL522312
CZECH REPUBLIC00101
GREECE01001
MALAYSIA21104
POLAND11024
SPAIN11103
TAIWAN00101
THAILAND01023
TURKEY12227
08

Study locations

66 sites
  • Santa Casa de Misericordia de Belo Horizonte
    Belo Horizonte, 30150-221, Brazil
  • Sociedade Beneficente de Senhoras - Hospital Sirio Libanes HSL Unidade Brasilia
    Brasília, 70200-730, Brazil
  • Ynova Pesquisa Clinica
    Florianópolis, 88020-210, Brazil
  • Liga Norte Riograndense Contra O Cancer
    Natal, 59062-000, Brazil
  • Complexo Hospitalar de Niteroi
    Niterói, 24020-096, Brazil
  • Irmandade Santa Casa de Misericordia de Porto Alegre
    Porto Alegre, 90050 170, Brazil
  • Hospital Das Clinicas Da Faculdade De Medicina De RPUSP HCRP
    Ribeirão Preto, 14051-140, Brazil
  • Oncoclinicas Rio de Janeiro S A
    Rio de Janeiro, 22 250 905, Brazil
  • Instituto de Ensino e Pesquisa Sao Lucas - IEP HEMOMED
    São Paulo, 01236-030, Brazil
  • Instituto D Or de Pesquisa e Ensino IDOR
    São Paulo, 04501-000, Brazil
  • Casa de Saude Santa Marcelina - Hospital Santa Marcelina
    São Paulo, 08270-120, Brazil
  • Fakultni Nemocnice Ostrava
    Ostrava, 708 52, Czechia
  • Fakultni nemocnice Kralovske Vinohrady
    Prague, 100 34, Czechia
  • General University Hospital in Prague
    Prague, 128 08, Czechia
  • Attikon University General Hospital of Attica
    Athens, 12462, Greece
  • University Hospital of Ioannina
    Ioannina, 45110, Greece
  • G.Papanikolaou
    Thessaloniki, 57010, Greece
  • Healthcare Global (HCG) Hospital
    Bangalore, 560027, India
  • American Oncology Institute Cancer Treatment Hospital Hyderabad
    Hyderabad, 500019, India
  • Bhagwan Mahaveer Cancer Hospital & Research Centre
    Jaipur, 302017, India
  • HCG cancer center
    Jaipur, 302020, India
  • Tata Medical Center
    Kolkata, 700156, India
  • AMRI Hospital, Mukundapur
    Mukundapur, 700099, India
  • Deenanath Mangeshkar Hospital and Research Centre
    Pune, 411004, India
  • Synergy Superspeciality Hospital
    Rajkot, 360005, India
  • Hospital Ampang
    Ampang, 68000, Malaysia
  • Hospital Sultanah Aminah
    Johor Bharu, 80100, Malaysia
  • Hospital Queen Elizabeth
    Kota Kinabalu, 88586, Malaysia
  • University Malaya Medical Centre
    Kuala Lumpur, 59100, Malaysia
  • Subang Jaya Medical Centre
    Subang Jaya, 47500, Malaysia
  • Szpital Specjalistyczny w Brzozowie Podkarpacki Osrodek Onkologiczny im Ks B Markiewicza
    Brzozów, 36 200, Poland
  • Swietokrzyskie Centrum Onkologii SPZOZ w Kielcach
    Kielce, 25 734, Poland
  • Uniwersytecki Szpital Kliniczny Nr 1 w Lublinie
    Lublin, 20-081, Poland
  • Szpital Specjalistyczny im Jedrzeja Sniadeckiego w Nowym Saczu
    Nowy Sącz, 33 300, Poland
  • SPZOZ Ministerstwa Spraw Wewnetrznych z Warminsko Mazurskim Centrum Onkologii w Olsztynie
    Olsztyn, 10-228, Poland
  • Centrum Medyczne Pratia Poznan
    Skorzewo, 60 185, Poland
  • Samodzielny Publiczny Szpital Kliniczny Nr 1 PUM im prof Tadeusza Sokolowskiego w Szczecinie
    Szczecin, 71252, Poland
  • Narodowy Instytut Onkologii im Marii Sklodowskiej Curie Panstwowy Instytut Badawczy
    Warsaw, 02-781, Poland
  • Specjalistyczny Szpital im dra Alfreda Sokolowskiego w Walbrzychu
    Wałbrzych, 58 309, Poland
  • Auxilio Mutuo Cancer Center
    San Juan, 00918, Puerto Rico
  • Spitalul Clinic Coltea
    Bucharest, 030167, Romania
  • Ovidius Clinical Hospital OCH
    Ovidiu, 905900, Romania
  • Hosp Reina Sofia
    Córdoba, 14004, Spain
  • Hosp. Univ. Infanta Leonor
    Madrid, 28031, Spain
  • Clinica Univ. de Navarra
    Pamplona, 31008, Spain
  • Hosp. Quiron Madrid Pozuelo
    Pozuelo de Alarcón, 28223, Spain
  • Hosp Clinico Univ de Salamanca
    Salamanca, 37007, Spain
  • Falu Lasarett Medicinkliniken Falun
    Falun, 791 82, Sweden
  • Sunderby Sjukhus
    Luleå, 97180, Sweden
  • Kaohsiung Medical University Chung Ho Memorial Hospital
    Kaohsiung City, 80756, Taiwan
  • China Medical University Hospital
    Taichung, 404327, Taiwan
  • Chi Mei Medical Center Liu Ying
    Tainan, 736, Taiwan
  • National Taiwan University Hospital
    Taipei, 100, Taiwan
  • King Chulalongkorn Memorial Hospital
    Bangkok, 10330, Thailand
  • Phramongkutklao Hospital and Medical College
    Bangkok, 10400, Thailand
  • Ramathibodi Hospital
    Bangkok, 10400, Thailand
  • Siriraj Hospital
    Bangkok, 10700, Thailand
  • Maharaj Nakorn Chiang Mai hospital Faculty of Medicine
    Chiang Mai, 50200, Thailand
  • Srinagarind Hospital
    Khon Kaen, 40002, Thailand
  • Ankara Bilkent Sehir Hastanesi
    Ankara Sehir Hastanesi, 06800, Turkey (Türkiye)
  • Ondokuz Mayis University
    Atakum, 55270, Turkey (Türkiye)
  • Trakya University Medical Faculty
    Edirne, 22030, Turkey (Türkiye)
  • Medipol Mega University Hospital
    Istanbul, 34214, Turkey (Türkiye)
  • Istanbul University
    Istanbul, 34390, Turkey (Türkiye)
  • Ege Universitesi Tip Fakultesi
    Izmir, 35100, Turkey (Türkiye)
  • Sakarya Egitim Ve Arastırma Hastanesi Korucuk Kampus
    Sakarya, 54290, Turkey (Türkiye)
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Data sharing details ↗ · www.janssen.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2022 to primary completion in Dec 2023, 12 months.

Results were first posted in Jan 2025, 1 year 1 month after primary completion.

Of 30 industry-sponsored phase 2 interventional studies under Lymphoma, Mantle-Cell, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 87. This study's 12 months is below that.

Counting every sponsor, half of 183 studies reached it within 63 months; a quarter within 38 and three quarters within 106.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 30, 2022
First posted
Oct 3, 2022
StartActual
Dec 6, 2022
Primary completionActual
Dec 6, 2023
CompletionActual
Sep 26, 2024
Results first posted
Jan 13, 2025
Last update
Oct 7, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 7, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05564052
Collaborators
Pharmacyclics LLC.
Responsible party
Sponsor
First posted
Oct 3, 2022
Start date
Dec 6, 2022
Primary completion
Dec 6, 2023
Completion
Sep 26, 2024
Results posted
Jan 13, 2025
Last update
Oct 7, 2025

Study contacts

Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ibrutinib · Lenalidomide · Bortezomib

Start the discussion